PolyPid to Showcase D-PLEX100 at Upcoming KOL Webinar
PolyPid Ltd. (Nasdaq: PYPD), a groundbreaking biopharmaceutical company renowned for its innovative approaches to surgical care, has exciting news. The company is set to participate in a virtual Key Opinion Leader (KOL) event organized by ROTH Capital Partners, aiming to discuss revolutionary advancements in postoperative care. This significant event will shed light on the potential of D-PLEX100, PolyPid's leading therapeutic candidate, which has the capacity to transform surgical practices and dramatically enhance patient outcomes.
KOL Event Details
The upcoming virtual event is a crucial opportunity for healthcare professionals and stakeholders to delve into the science behind D-PLEX100 and its impact on preventing surgical site infections (SSIs). The KOL webinar, titled "The Science and Business Case for D-PLEX100 (Tackling Surgical Site Infections)," is scheduled for December 10, 2025.
Key Information about the Webinar
This informative session will commence at 11:30 AM Eastern Time. It promises to be an engaging discussion centered on the clinical significance and economic implications of SSIs, which are a prevailing concern in surgical settings. Attendees can expect a comprehensive overview of current SSI prevention methods, their limitations, and how D-PLEX100 provides a compelling solution.
Featured Speaker and Moderator
The webinar will feature esteemed speaker Dr. Steven D. Wexner, an internationally recognized expert in colorectal surgery. Dr. Wexner, who serves as the Executive Director and System Chief for Colorectal Surgery at MedStar Georgetown University Hospital, will guide attendees through the pressing challenges associated with SSIs. Attendees will have the chance to engage directly with both Dr. Wexner and PolyPid's management team during a live Q&A session following the presentation.
Meet Dr. Steven D. Wexner
With an extensive career spanning over 38 years, Dr. Wexner is a stalwart in the field of colorectal surgery, boasting a remarkable record of clinical excellence and educational contributions. His insights into the intricate relationship between surgical techniques and infection prevention will be invaluable to participants interested in improving surgical outcomes.
The Innovation of D-PLEX100
D-PLEX100, PolyPid’s flagship product, aims to tackle the challenge of SSIs with its advanced Polymer-Lipid Encapsulation matriX (PLEX) technology. This innovative delivery system ensures prolonged antimicrobial activity directly at the surgical site, substantially mitigating the risk of infections. Following its successful Phase 3 SHIELD II trial, which highlighted a remarkable 58% reduction in SSI incidence for patients undergoing colorectal surgery, D-PLEX100 has gained significant recognition in the medical community.
Significant Benefits of D-PLEX100
One of the major advantages of D-PLEX100 lies in its ability to release doxycycline—a broad-spectrum antibiotic—over an extended period, maintaining effective local concentrations for up to 30 days. This controlled release mechanism not only combats common pathogens but also shows promise in addressing antibiotic-resistant infections, which have become a growing concern in surgical practices.
The Vision of PolyPid
PolyPid Ltd. is dedicated to redefining postoperative care through its pioneering technologies. The company is committed to continuous innovation, with plans to submit a New Drug Application (NDA) for D-PLEX100, anticipated in early 2026. PolyPid has also expanded its pipeline to explore treatments for oncology, obesity, and diabetes, positioning itself at the forefront of medical advancements.
For additional information regarding PolyPid’s initiatives and updates, kindly visit their official website and connect on social media platforms to stay informed about their latest breakthroughs in healthcare.
Frequently Asked Questions
What is the purpose of the KOL event that PolyPid is hosting?
The KOL event aims to discuss the significance of D-PLEX100 in preventing surgical site infections and improving surgical outcomes.
Who will be speaking at the webinar?
Dr. Steven D. Wexner, an expert in colorectal surgery, will be the keynote speaker at the webinar.
What is D-PLEX100?
D-PLEX100 is PolyPid's leading product candidate designed to prevent surgical site infections through localized, controlled release of antibiotics.
When is the KOL event scheduled?
The KOL event is scheduled for December 10, 2025, at 11:30 AM Eastern Time.
How can I attend the webinar?
Interested participants can register for the webinar through the provided registration link, which will be available on the event day.
